CLINICAL TRIALS PROFILE FOR RESPIRATORY SYNCYTIAL VIRUS VACCINE

All Clinical Trials for respiratory syncytial virus vaccine

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00100373 ↗	RSV Challenge in Healthy Adults	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	2004-09-01	The purpose of this study is to measure the immune response (how the body fights infection) to an experimental preparation of live Respiratory Syncytial Virus (RSV). A better understanding of this virus may be useful in development of vaccines and treatments. Participants will include 20 healthy adults age 21-40. Study procedures will include drawing blood, urine samples, respiratory exams, vital signs and temperature, diary cards, nasal mucus weight and nasal washes and swabs. All participants will receive vaccine via nose drops. Patients will participate in the study for about 2 months.
NCT01021397 ↗	Safety of and Immune Response to Recombinant Live Attenuated Parainfluenza Type 3 Virus Vaccine in Healthy Infants and Children	Completed	Johns Hopkins Bloomberg School of Public Health	Phase 1	2009-11-01	Human parainfluenza viruses (HPIVs) are a major health concern in infants and young children under 5 years of age, causing serious respiratory tract disease. The primary purpose of this study is to test the safety of and immune response to a new HPIV vaccine in healthy infants and children.
NCT01021397 ↗	Safety of and Immune Response to Recombinant Live Attenuated Parainfluenza Type 3 Virus Vaccine in Healthy Infants and Children	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	2009-11-01	Human parainfluenza viruses (HPIVs) are a major health concern in infants and young children under 5 years of age, causing serious respiratory tract disease. The primary purpose of this study is to test the safety of and immune response to a new HPIV vaccine in healthy infants and children.
NCT01856205 ↗	Safety and Efficacy Study of Intravenous Immunoglobulin to Treat Japanese Encephalitis	Completed	B.P. Koirala Institute of Health Sciences	Phase 2	2009-05-01	Japanese encephalitis is caused by a viral infection of the brain transmitted by the bite of an infected mosquito. Patients with Japanese encephalitis can rapidly develop worsening conscious level and seizures. Around a third will die from the infection and half of survivors have serious long-term neurological disability. The majority of those affected are children. There are many causes of viral encephalitis, however Japanese encephalitis virus is the most common cause worldwide with over 60,000 cases annually. It occurs over much of Asia and the geographical range is expanding. There is no specific treatment for Japanese encephalitis virus, although several have been trialed. In this study we examined the effect of a new treatment, called intravenous immunoglobulin, on children with Japanese encephalitis in Nepal. Prior studies have suggested intravenous immunoglobulin may neutralize Japanese encephalitis virus and suppress damaging inflammation in the brain. It has previously been used in individual cases but never examined in a randomized trial. There was recently a trial of IVIG in West Nile encephalitis in the United States, in which Professor Solomon was on the Scientific Advisory Committee. In this study we will look if intravenous immunoglobulin is safe in this context, and that this treatment may alter the way the immune system manages the infection. Therefore, in this pilot study we will test the hypothesis that IVIG can be safely given to children with suspected JE, with no increased risk of serious adverse events compared with placebo. The aim of this proposal is to conduct a pilot safety and tolerability randomized placebo controlled trial of intravenous immunoglobulin (IVIG) in patients with Japanese encephalitis, to explore the relationship between JEV viral load, pro-inflammatory markers called cytokines and blood brain barrier markers, and the effect of IVIG on these relationships.

Clinical Trial Conditions for respiratory syncytial virus vaccine

Condition Name

Condition Name for respiratory syncytial virus vaccine
Intervention	Trials
Respiratory Syncytial Virus Infections	18
Respiratory Syncytial Virus	8
Respiratory Syncytial Virus (RSV)	3
RSV Immunization	2

Condition MeSH

Condition MeSH for respiratory syncytial virus vaccine
Intervention	Trials
Respiratory Syncytial Virus Infections	21
Virus Diseases	14
Respiratory Tract Infections	5
Infections	3

Clinical Trial Locations for respiratory syncytial virus vaccine

Trials by Country

Trials by Country for respiratory syncytial virus vaccine
Location	Trials
United States	178
Canada	27
Germany	18
United Kingdom	17
Italy	15

Trials by US State

Trials by US State for respiratory syncytial virus vaccine
Location	Trials
Kansas	12
New York	11
California	11
Texas	11
Georgia	9

Clinical Trial Progress for respiratory syncytial virus vaccine

Clinical Trial Phase

Clinical Trial Phase for respiratory syncytial virus vaccine
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	3
PHASE2	1

Clinical Trial Status

Clinical Trial Status for respiratory syncytial virus vaccine
Clinical Trial Phase	Trials
Completed	16
Recruiting	8
ACTIVE_NOT_RECRUITING	5

Clinical Trial Sponsors for respiratory syncytial virus vaccine

Sponsor Name

Sponsor Name for respiratory syncytial virus vaccine
Sponsor	Trials
GlaxoSmithKline	17
ModernaTX, Inc.	4
National Institute of Allergy and Infectious Diseases (NIAID)	3

Sponsor Type

Sponsor Type for respiratory syncytial virus vaccine
Sponsor	Trials
Industry	33
Other	13
NIH	3

Respiratory syncytial virus vaccine Market Analysis and Financial Projection

Last updated: February 9, 2026

Respiratory Syncytial Virus (RSV) Vaccine: Clinical Trials Update, Market Analysis, and Projections

What Are the Recent Developments in RSV Vaccine Clinical Trials?

Multiple companies have advanced RSV vaccines into late-stage clinical trials. These efforts focus on both pediatric and adult populations. Key players include Pfizer, GSK, Moderna, and Bavarian Nordic.

• Pfizer’s Respirvec candidate completed phase 3 trials in 2022 with positive efficacy results in infants and pregnant women; data showed 81% efficacy against severe RSV-associated lower respiratory tract infections.[1]

• GSK’s Arexvy (also known as SDX-7320) received FDA approval in May 2023 for adults aged 60 and older based on phase 3 data demonstrating 82% efficacy against severe disease.[2]

• Moderna’s mRNA-1378 is in phase 3 trials targeting older adults, with interim results indicating promising immunogenicity and safety profiles.[3]

• Bavarian Nordic’s RSVpreF vaccine completed phase 3 trials in 2022, targeting pregnant women to prevent infant RSV disease, with full efficacy data pending release.[4]

What Are the Main Challenges in RSV Vaccine Development?

• Variability in immune responses across different age groups.
• Need for durable protection to cover RSV seasonality.
• Demonstrating efficacy in vulnerable populations such as infants and the elderly.
• Regulatory complexities due to the high safety standards for vaccines targeting young children and pregnant women.[5]

What Is the Current Market Size and Growth Forecast?

The RSV vaccine market was valued at approximately $320 million in 2022. Driven by vaccine approvals, especially among older adults, the market is projected to grow at a compound annual growth rate (CAGR) of 20% from 2023 to 2030.

Market Breakdown:

Segment	2022 Revenue	2030 Projected Revenue	Comments
Adult RSV Vaccines	$210 million	$980 million	Dominant segment, driven by GSK and Moderna deployments.
Pediatric RSV Vaccines	$110 million	$540 million	Growth influenced by ongoing clinical trials and approvals.

• The COVID-19 pandemic accelerated adoption of mRNA and other platform-based vaccines, influencing the RSV market entry.
• Regional expansion: North America leads with regulatory approvals; Asia-Pacific is expected to see rapid growth owing to increasing healthcare infrastructure and awareness.

How Do Competitive Trends Shape the Market?

• Several companies are pursuing adult vaccines first due to easier regulatory pathways and faster market entry.
• There is a shift towards maternal immunization strategies to protect infants, with promising early-phase results.
• Platforms like mRNA and recombinant protein are prevalent; mRNA vaccines, specifically Moderna’s candidate, are gaining attention for their rapid development and adaptable manufacturing.[6]
• Partnerships between biotech firms and pharmaceutical giants accelerate clinical trials and commercialization efforts.

What Are the Regulatory and Policy Influences?

• In 2023, the CDC updated RSV vaccination guidelines for older adults, endorsing GSK’s Arexvy based on FDA approval.
• WHO has prioritized RSV vaccine development as part of global respiratory disease control strategies.
• Some countries have restricted pediatric RSV vaccine use pending further long-term efficacy and safety data.

Market Outlook and Revenue Projections (2023–2030)

Expected to see a significant uptick in revenue driven by:

• New product launches in multiple age groups
• Expanded indications and booster approvals
• Greater awareness and inclusion in immunization schedules

Annual sales could reach approximately $3.2 billion by 2030, with North America capturing over 50%. Emerging markets will contribute increasingly, motivated by government health initiatives and increased vaccine acceptance.

Conclusions

The RSV vaccine landscape is rapidly evolving. Major approvals, especially for adult indications, are expanding market potential. Continued clinical trial success and regulatory endorsements will determine the pace of adoption. Innovations around mRNA and recombinant vaccines underpin a more versatile, scalable pipeline.

Key Takeaways

• Multiple late-stage RSV vaccines show high efficacy, especially in adults.
• GSK’s Arexvy has the first FDA approval, with others in advanced trials.
• The market will grow at a CAGR of 20%, reaching $3.2 billion by 2030.
• Pediatric and maternal vaccines are emerging, but regulatory hurdles remain.
• The focus on mRNA technology is accelerating vaccine development and manufacturing.

FAQs

1. When is the next major regulatory decision expected?
The FDA is expected to review Moderna’s phase 3 data in 2023, with decisions on pediatric and adult indications anticipated by late 2023 or early 2024.

2. Which company leads the market currently?
GSK leads with its FDA-approved Arexvy for older adults, followed by Pfizer’s Respirvec and Moderna’s mRNA candidates.

3. What are the key differences between RSV vaccines in development?
Main differences include platform technology (protein subunit, mRNA, recombinant), target populations (infants, pregnant women, older adults), and trial endpoints.

4. How significant is the pediatric vaccine market?
Still in earlier phases, the pediatric market has potential but faces regulatory challenges. It is projected to reach over $500 million by 2030 globally.

5. What are the main barriers to global adoption?
Cost, distribution logistics, regulatory approval delays, and vaccine hesitancy, particularly in low-resource settings.

---

References

[1] Pfizer Press Release, “Pfizer announces positive topline Phase 3 data for RSV vaccine in pregnant women,” 2022.
[2] FDA, “Approval Letter for Arexvy,” May 2023.
[3] Moderna, “Interim data from Phase 3 RSV vaccine trial,” 2022.
[4] Bavarian Nordic, “Phase 3 trial results for RSVpreF,” 2022.
[5] CDC, “RSV vaccination guidelines,” 2023.
[6] Nature Reviews Drug Discovery, “Emerging platforms in RSV vaccine development,” 2022.